Document is current
Any future updates will be listed below
-
Authors
Bilgrami, Zarina R. https://orcid.org/0000-0002-5996-415X
Castro, Eduardo https://orcid.org/0000-0002-7788-9069
Agurto, Carla https://orcid.org/0000-0002-0617-4488
Liebenthal, Einat
Ennis, Michaela
Baker, Justin T.
Scott, Isabelle
Colton, Beau-Luke
Cho, Kang Ik K. https://orcid.org/0000-0001-7135-3848
Li, Linying
Tamayo, Zailyn
Henecks, Mara
Rahimi Eichi, Habiballah
Henry, Tae’lar
Addington, Jean https://orcid.org/0000-0002-8298-0756
Alameda, Luis K. https://orcid.org/0000-0002-8621-2885
Arango, Celso https://orcid.org/0000-0003-3382-4754
Breitborde, Nicholas J. K.
Broome, Matthew R. https://orcid.org/0000-0002-6963-8884
Cadenhead, Kristin S. https://orcid.org/0000-0002-5952-4605
Calkins, Monica E.
Chen, Eric Yu Hai https://orcid.org/0000-0002-5247-3593
Choi, Jimmy
Conus, Philippe
Cornblatt, Barbara A.
Ellman, Lauren M.
Fusar-Poli, Paolo
Gaspar, Pablo A. https://orcid.org/0000-0002-9682-5327
Gerber, Carla
Glenthøj, Louise Birkedal
Horton, Leslie E.
Hui, Christy
Kambeitz, Joseph https://orcid.org/0000-0002-8988-3959
Kambeitz-Ilankovic, Lana
Keshavan, Matcheri S.
Kim, Sung-Wan https://orcid.org/0000-0002-6739-2163
Koutsouleris, Nikolaos https://orcid.org/0000-0001-6825-6262
Kwon, Jun Soo https://orcid.org/0000-0002-1060-1462
Langbein, Kerstin
Mamah, Daniel
Diaz-Caneja, Covadonga M. https://orcid.org/0000-0001-8538-3175
Mathalon, Daniel H. https://orcid.org/0000-0001-6090-4974
Mittal, Vijay A. https://orcid.org/0000-0001-9017-5119
Nordentoft, Merete
Pearlson, Godfrey D.
Perez, Jesus
Perkins, Diana O. https://orcid.org/0000-0001-9396-2206
Powers, Albert R. III https://orcid.org/0000-0003-3057-5043
Rogers, Jack
Sabb, Fred W.
Schiffman, Jason
Shah, Jai L. https://orcid.org/0000-0002-7549-6990
Silverstein, Steven M. https://orcid.org/0000-0002-0699-0960
Smesny, Stefan
Stone, William S. https://orcid.org/0000-0003-2932-7288
Yassin, Walid https://orcid.org/0000-0001-9612-0485
Strauss, Gregory P.
Thompson, Judy L.
Upthegrove, Rachel https://orcid.org/0000-0001-8204-5103
Verma, Swapna
Wang, Jijun https://orcid.org/0000-0001-5427-7425
Wolf, Daniel H. https://orcid.org/0000-0002-9731-8781
McGorry, Patrick D.
Kahn, Rene S. https://orcid.org/0000-0001-5909-8004
Kane, John M.
Anticevic, Alan
Bearden, Carrie E. https://orcid.org/0000-0002-8516-923X
Dwyer, Dominic https://orcid.org/0000-0003-3949-5867
Billah, Tashrif
Bouix, Sylvain https://orcid.org/0000-0003-1326-6054
Pasternak, Ofer
Shenton, Martha E. https://orcid.org/0000-0003-4235-7879
Woods, Scott W. https://orcid.org/0000-0002-3103-5228
Nelson, Barnaby
,
Cecchi, Guillermo A. https://orcid.org/0000-0003-1013-8348
Corcoran, Cheryl M. https://orcid.org/0000-0002-8902-4353
Wolff, Phillip M.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (U01MH124639)
- License Information
-
More Information
Article History
Received: 28 August 2024
Accepted: 21 August 2025
First Online: 15 October 2025
Competing Interests
: The authors declare the following competing interests: K.A. is on the Australian Cognitive Impairment Associated with Schizophrenia Advisory Board for Boehringer Ingelheim and receives honorary funds. D.D. has received honorary funds for one educational seminar for CSL Sequiris. A.A. is a cofounder, serves as a member of the Board of Directors, as a scientific adviser, and holds equity in Manifest Technologies, Inc., and is a coinventor on the following patent: Anticevic A, Murray JD, and Ji JL: Systems and Methods for NeuroBehavioral Relationships in Dimensional Geometric Embedding, PCT International Application No. PCT/US2119/022110, filed Mar 13, 2019. E.C. has received speaker fees at non-promotional educational events. P.F.-P. has received research funds or personal fees from Lundbeck, Angelini, Menarini, Sunovion, Boehringer Ingelheim, Proxymm Science, Otsuka, outside the current study. J.K. has received speaking or consulting fees from Janssen, Boehringer Ingelheim, ROVI, and Lundbeck. C.M.D.-C. has received grant support from Instituto de Salud Carlos III, Spanish Ministry of Science and Innovation, and honoraria or travel support from Angelini, Janssen, and Viatris; RU has received speaker fees at a non-promotional educational event: Otsuka: Consultancy for Viatris and Springer Healthcare. Honorary General Secretary, British Association for Psychopharmacology (unpaid). J.M.K. is a consultant to or receives honoraria and/or travel support and/or speakers bureau: Alkermes, Allergan, Boehringer-Ingelheim, Cerevel, Dainippon Sumitomo, H. Lundbeck, HealthRhythms, HLS Therapeutics, Indivior, Intracellular Therapies, Janssen Pharmaceutical, Johnson & Johnson, Karuna Therapeutics/Bristol Meyer-Squibb, LB Pharmaceuticals, Mapi, Maplight, Merck, Minerva, Neurocrine, Newron, Novartis, NW PharmaTech, Otsuka, Roche, Saladax, Sunovion, Teva; RSK provides consulting to Alkermes, Boehringer-Ingelheim. S.W.W. has received speaking fees from the American Psychiatric Association and from Medscape Features. He has been granted a US patent no. 8492418 B2 for a method of treating prodromal schizophrenia with glycine agonizts. He owns stock in NW PharmaTech. C.A. has been a consultant to or has received honoraria or grants from Acadia, Angelini, Biogen, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Medscape, Menarini, Minerva, Otsuka, Pfizer, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion, and Takeda; GDH has been a consultant for Bristol Myers Squibb. P.J.M. has been a consultant for Otsuka and TEVA; and Z.T. has been a consultant for Manifest Technologies. C.M.C. is an Associate Editor of Schizophrenia. All other authors report no competing interests.
